Meridian Bioscience, Inc. (VIVO) Tops Q2 EPS by 2c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $4.36 +3.56%
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $47.4 million versus the consensus estimate of $44.82 million.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
